279 related articles for article (PubMed ID: 23598850)
1. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.
Aiello Bowles EJ; Boudreau DM; Chubak J; Yu O; Fujii M; Chestnut J; Buist DS
J Oncol Pract; 2012 Nov; 8(6):e149-57. PubMed ID: 23598850
[TBL] [Abstract][Full Text] [Related]
2. Clinical consultations and investigations before and after discontinuation of endocrine therapy in women with primary breast cancer.
Lopez D; Kemp-Casey A; Saunders C; Roughead E; Boyle F; Bulsara M; Preen D
Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765859
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
4. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
6. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
7. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Hershman DL; Kushi LH; Shao T; Buono D; Kershenbaum A; Tsai WY; Fehrenbacher L; Gomez SL; Miles S; Neugut AI
J Clin Oncol; 2010 Sep; 28(27):4120-8. PubMed ID: 20585090
[TBL] [Abstract][Full Text] [Related]
8. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
10. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.
Wulaningsih W; Garmo H; Ahlgren J; Holmberg L; Folkvaljon Y; Wigertz A; Van Hemelrijck M; Lambe M
Breast Cancer Res Treat; 2018 Nov; 172(1):167-177. PubMed ID: 30030708
[TBL] [Abstract][Full Text] [Related]
11. Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; Liefers GJ; Nortier JWR; Rutgers EJT; Seynaeve CM; van de Velde CJH;
Eur J Cancer; 2018 May; 95():59-67. PubMed ID: 29635145
[TBL] [Abstract][Full Text] [Related]
12. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis.
van Herk-Sukel MP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Coebergh JW; Herings RM
Breast Cancer Res Treat; 2010 Aug; 122(3):843-51. PubMed ID: 20058066
[TBL] [Abstract][Full Text] [Related]
13. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
15. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
16. Primary endocrine therapy as an approach for patients with localized breast cancer deemed not to be surgical candidates.
Hilton J; Arnaout A; Clemons M
Curr Opin Support Palliat Care; 2014 Mar; 8(1):53-8. PubMed ID: 24299966
[TBL] [Abstract][Full Text] [Related]
17. Evolution in the risk of adverse events of adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer.
Reinhorn D; Yerushalmi R; Moore A; Desnoyers A; Saleh RR; Amir E; Goldvaser H
Breast Cancer Res Treat; 2020 Jul; 182(2):259-266. PubMed ID: 32488391
[TBL] [Abstract][Full Text] [Related]
18. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
Hershman DL; Tsui J; Meyer J; Glied S; Hillyer GC; Wright JD; Neugut AI
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25349080
[TBL] [Abstract][Full Text] [Related]
19. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
20. Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.
Ferreira AR; Palha A; Correia L; Filipe P; Rodrigues V; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; Lin NU; Costa L; Vaz-Luis I
Breast; 2018 Feb; 37():107-113. PubMed ID: 29131988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
